Search

Your search keyword '"Rosing, Hilde"' showing total 1,337 results
Start Over Author "Rosing, Hilde"
1,337 results on '"Rosing, Hilde"'

16. Platinum retention in plasma, urine, and normal colonic mucosa in cisplatin-treated testicular cancer survivors.

Author

Breekveldt, Emilie C. H., Ykema, Berbel L. M., Huitema, Alwin D. R., Gietema, Jourik A., Beijnen, Jos H., Snaebjornsson, Petur, Schaapveld, Michael, van Leeuwen, Flora E., Rosing, Hilde, and van Leerdam, Monique E.

Abstract

Testicular cancer survivors (TCS) treated with platinum-based chemotherapy have increased cancer risk. Platinum retention in healthy tissue may contribute to carcinogenesis. We assessed total platinum concentrations in plasma, urine, and normal colonic mucosa samples in TCS treated with cisplatin. From the total TCS treated with ≥3 cycles cisplatin who participated in a colonoscopy-screening study in four Dutch hospitals (n = 154), plasma (n = 131) and urine (n = 115) samples were collected. During colonoscopy, 60 biopsies of normal colonic mucosa (two samples each per 30 randomly selected patients undergoing colonoscopy) were obtained. Samples were analyzed for total platinum concentrations using inductively coupled plasma mass spectrometry and compared with controls (plasma: 10, urine: 3, normal colonic mucosa: 9). The median age at colonoscopy was 50 years (interquartile range (IQR): 43–57) and the median time since treatment was 20 years (IQR:16–26). Median platinum concentrations in plasma (38 pg/mL; IQR: 24–61 pg/mL) and urine (376 pg/mL; IQR: 208–698 pg/mL) remained elevated in TCS up to 40 years post-treatment and were higher than in controls (all controls were below limits of detection [plasma: 25 pg/mL, urine: 6 pg/mL]). The median platinum concentration in normal colonic mucosa was 0.58 pg/mg (IQR: 0.33–1.59 pg/mg) in the transverse and 0.51 pg/mg (IQR:0.26–1.25 pg/mg) in the descending colon. Cisplatin treatment is associated with long-term retention of platinum in various patient sample types. This might increase cancer risk by causing somatic mutations, potentially explaining the elevated risk of second malignant neoplasms in TCS. The long-term effects of platinum retention should be monitored to understand carcinogenesis and to provide guidelines for early second cancer detection. Trial registration: ClinicalTrials.Gov:NCT04180033. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

18. Heterogeneous drug penetrance of veliparib and carboplatin measured in triple negative breast tumors

Author

Bartelink, Imke H, Prideaux, Brendan, Krings, Gregor, Wilmes, Lisa, Lee, Pei Rong Evelyn, Bo, Pan, Hann, Byron, Coppé, Jean-Philippe, Heditsian, Diane, Swigart-Brown, Lamorna, Jones, Ella F, Magnitsky, Sergey, Keizer, Ron J, de Vries, Niels, Rosing, Hilde, Pawlowska, Nela, Thomas, Scott, Dhawan, Mallika, Aggarwal, Rahul, Munster, Pamela N, Esserman, Laura J, Ruan, Weiming, Wu, Alan HB, Yee, Douglas, Dartois, Véronique, Savic, Radojka M, Wolf, Denise M, and van ’t Veer, Laura

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Breast Cancer, Brain Disorders, Cancer, Clinical Research, 5.1 Pharmaceuticals, Development of treatments and therapeutic interventions, Animals, Benzimidazoles, Carboplatin, Cell Line, Tumor, Female, Humans, Leukocytes, Mononuclear, Mice, Penetrance, Poly(ADP-ribose) Polymerase Inhibitors, Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization, Triple Negative Breast Neoplasms, Xenograft Model Antitumor Assays, Drug penetration, Spatial heterogeneity, Pharmacokinetics, Matrix-assisted laser desorption/ionization mass spectrometric imaging, Poly(ADP-ribose) polymerase inhibitors, Inductively coupled plasma-mass spectrometry, Inductively coupled plasma–mass spectrometry, Oncology & Carcinogenesis, Oncology and carcinogenesis
Abstract

BackgroundPoly(ADP-ribose) polymerase inhibitors (PARPi), coupled to a DNA damaging agent is a promising approach to treating triple negative breast cancer (TNBC). However, not all patients respond; we hypothesize that non-response in some patients may be due to insufficient drug penetration. As a first step to testing this hypothesis, we quantified and visualized veliparib and carboplatin penetration in mouse xenograft TNBCs and patient blood samples.MethodsMDA-MB-231, HCC70 or MDA-MB-436 human TNBC cells were implanted in 41 beige SCID mice. Low dose (20 mg/kg) or high dose (60 mg/kg) veliparib was given three times daily for three days, with carboplatin (60 mg/kg) administered twice. In addition, blood samples were analyzed from 19 patients from a phase 1 study of carboplatin + PARPi talazoparib. Veliparib and carboplatin was quantified using liquid chromatography-mass spectrometry (LC-MS). Veliparib tissue penetration was visualized using matrix-assisted laser desorption/ionization mass spectrometric imaging (MALDI-MSI) and platinum adducts (covalent nuclear DNA-binding) were quantified using inductively coupled plasma-mass spectrometry (ICP-MS). Pharmacokinetic modeling and Pearson's correlation were used to explore associations between concentrations in plasma, tumor cells and peripheral blood mononuclear cells (PBMCs).ResultsVeliparib penetration in xenograft tumors was highly heterogeneous between and within tumors. Only 35% (CI 95% 26-44%), 74% (40-97%) and 46% (9-37%) of veliparib observed in plasma penetrated into MDA-MB-231, HCC70 and MDA-MB-436 cell-based xenografts, respectively. Within tumors, penetration heterogeneity was larger with the 60 mg/kg compared to the 20 mg/kg dose (RSD 155% versus 255%, P = 0.001). These tumor concentrations were predicted similar to clinical dosing levels, but predicted tumor concentrations were below half maximal concentration values as threshold of response. Xenograft veliparib concentrations correlated positively with platinum adduct formation (R 2 = 0.657), but no PARPi-platinum interaction was observed in patients' PBMCs. Platinum adduct formation was significantly higher in five gBRCA carriers (ratio of platinum in DNA in PBMCs/plasma 0.64% (IQR 0.60-1.16%) compared to nine non-carriers (ratio 0.29% (IQR 0.21-0.66%, P

Published
2017

19. A proof-of-concept study of sequential treatment with the HDAC inhibitor vorinostat following BRAF and MEK inhibitors in BRAFV600mutated melanoma

Author

Embaby, Alaa, primary, Huijberts, Sanne C.F.A., additional, Wang, Liqin, additional, Leite de Oliveira, Rodrigo, additional, Rosing, Hilde, additional, Nuijen, Bastiaan, additional, Sanders, Joyce, additional, Hofland, Ingrid, additional, van Steenis, Charlaine, additional, Kluin, Roelof J.C., additional, Lieftink, Cor, additional, Smith, Christopher G., additional, Blank, Christian U., additional, van Thienen, Johannes V., additional, Haanen, John B.A.G., additional, Steeghs, Neeltje, additional, Opdam, Frans L., additional, Beijnen, Jos H., additional, Huitema, Alwin D.R., additional, Bernards, Rene, additional, Schellens, Jan H.M., additional, and Wilgenhof, Sofie, additional

Published
2024
Full Text
View/download PDF

22. Analytical Validation of a Volumetric Absorptive Microsampling Method for Therapeutic Drug Monitoring of the Oral Targeted Anticancer Agents, Abiraterone, Alectinib, Cabozantinib, Imatinib, Olaparib, and Sunitinib, and Metabolites

Author

Apotheek O&O&O, Cancer, Meertens, Marinda, de Vries, Niels, Rosing, Hilde, Steeghs, Neeltje, Beijnen, Jos H, Huitema, Alwin D R, Apotheek O&O&O, Cancer, Meertens, Marinda, de Vries, Niels, Rosing, Hilde, Steeghs, Neeltje, Beijnen, Jos H, and Huitema, Alwin D R

Published
2024

23. Development and validation of an ultra-performance liquid chromatography-tandem mass spectrometry method for the quantification of the antimalarial drug pyronaridine in human whole blood

Author

Apotheek O&O&O, Cancer, Schouten, Wietse M., Roseboom, Ignace C., Lucas, Luc, Kabalu Tshiongo, Japhet, Muhindo Mavoko, Hypolite, Kayentao, Kassoum, Rosing, Hilde, Huitema, Alwin D.R., Beijnen, Jos H., Dorlo, Thomas P.C., Apotheek O&O&O, Cancer, Schouten, Wietse M., Roseboom, Ignace C., Lucas, Luc, Kabalu Tshiongo, Japhet, Muhindo Mavoko, Hypolite, Kayentao, Kassoum, Rosing, Hilde, Huitema, Alwin D.R., Beijnen, Jos H., and Dorlo, Thomas P.C.

Published
2024

25. A multiplex UPLC-MS/MS method for the quantification of three PD-L1 checkpoint inhibitors, atezolizumab, avelumab, and durvalumab, in human serum

Author

Apotheek O&O&O, Cancer, Buitelaar, Pauline L.M., de Jong, Karen A.M., Aardenburg, Leon, van der Heijden, Michiel S., Huitema, Alwin D.R., Beijnen, Jos H., Rosing, Hilde, Apotheek O&O&O, Cancer, Buitelaar, Pauline L.M., de Jong, Karen A.M., Aardenburg, Leon, van der Heijden, Michiel S., Huitema, Alwin D.R., Beijnen, Jos H., and Rosing, Hilde

Published
2024

26. A proof-of-concept study of sequential treatment with the HDAC inhibitor vorinostat following BRAF and MEK inhibitors in BRAFV600mutated melanoma

Author

Apotheek O&O&O, Cancer, Embaby, Alaa, Huijberts, Sanne C F A, Wang, Liqin, Leite de Oliveira, Rodrigo, Rosing, Hilde, Nuijen, Bastiaan, Sanders, Joyce, Hofland, Ingrid, van Steenis, Charlaine, Kluin, Roelof J C, Lieftink, Cor, Smith, Christopher G, Blank, Christian U, van Thienen, Johannes V, Haanen, John B A G, Steeghs, Neeltje, Opdam, Frans L, Beijnen, Jos H, Huitema, Alwin D R, Bernards, Rene, Schellens, Jan H M, Wilgenhof, Sofie, Apotheek O&O&O, Cancer, Embaby, Alaa, Huijberts, Sanne C F A, Wang, Liqin, Leite de Oliveira, Rodrigo, Rosing, Hilde, Nuijen, Bastiaan, Sanders, Joyce, Hofland, Ingrid, van Steenis, Charlaine, Kluin, Roelof J C, Lieftink, Cor, Smith, Christopher G, Blank, Christian U, van Thienen, Johannes V, Haanen, John B A G, Steeghs, Neeltje, Opdam, Frans L, Beijnen, Jos H, Huitema, Alwin D R, Bernards, Rene, Schellens, Jan H M, and Wilgenhof, Sofie

Published
2024

27. Is Higher Docetaxel Clearance in Prostate Cancer Patients Explained by Higher CYP3A? An In Vivo Phenotyping Study with Midazolam

Author

van der Heijden, Lisa T., Ribbers, Claire A., Vermunt, Marit A.C., Pluim, Dick, Acda, Manon, Tibben, Matthijs, Rosing, Hilde, Douma, Joeri A.J., Naipal, Kishan, Bergman, Andre M., Beijnen, Jos H., Huitema, Alwin D.R., Opdam, Frans L., van der Heijden, Lisa T., Ribbers, Claire A., Vermunt, Marit A.C., Pluim, Dick, Acda, Manon, Tibben, Matthijs, Rosing, Hilde, Douma, Joeri A.J., Naipal, Kishan, Bergman, Andre M., Beijnen, Jos H., Huitema, Alwin D.R., and Opdam, Frans L.

Abstract

Patients with prostate cancer (PCa) have a lower docetaxel exposure for both intravenous (1.8-fold) and oral administration (2.4-fold) than patients with other solid cancers, which could influence efficacy and toxicity. An altered metabolism by cytochrome P450 3A (CYP3A) due to castration status might explain the observed difference in docetaxel pharmacokinetics. In this in vivo phenotyping, pharmacokinetic study, CYP3A activity defined by midazolam clearance (CL) was compared between patients with PCa and male patients with other solid tumors. All patients with solid tumors who did not use CYP3A-modulating drugs were eligible for participation. Patients received 2 mg midazolam orally and 1 mg midazolam intravenously on 2 consecutive days. Plasma concentrations were measured with a validated liquid chromatography–tandem mass spectrometry method. Genotyping was performed for CYP3A4 and CYP3A5. Nine patients were included in each group. Oral midazolam CL was 1.26-fold higher in patients with PCa compared to patients with other solid tumors (geometric mean [coefficient of variation], 94.1 [33.5%] L/h vs 74.4 [39.1%] L/h, respectively; P =.08). Intravenous midazolam CL did not significantly differ between the 2 groups (P =.93). Moreover, the metabolic ratio of midazolam to 1′-hydroxy midazolam did not differ between the 2 groups for both oral administration (P =.67) and intravenous administration (P =.26). CYP3A4 and CYP3A5 genotypes did not influence midazolam pharmacokinetics. The observed difference in docetaxel pharmacokinetics between both patient groups therefore appears to be explained neither by a difference in midazolam CL nor by a difference in metabolic conversion rate of midazolam.

Published
2024

28. Is Higher Docetaxel Clearance in Prostate Cancer Patients Explained by Higher CYP3A? An In Vivo Phenotyping Study with Midazolam

Author

Unit Opleiding Aios, Apotheek O&O&O, Cancer, van der Heijden, Lisa T., Ribbers, Claire A., Vermunt, Marit A.C., Pluim, Dick, Acda, Manon, Tibben, Matthijs, Rosing, Hilde, Douma, Joeri A.J., Naipal, Kishan, Bergman, Andre M., Beijnen, Jos H., Huitema, Alwin D.R., Opdam, Frans L., Unit Opleiding Aios, Apotheek O&O&O, Cancer, van der Heijden, Lisa T., Ribbers, Claire A., Vermunt, Marit A.C., Pluim, Dick, Acda, Manon, Tibben, Matthijs, Rosing, Hilde, Douma, Joeri A.J., Naipal, Kishan, Bergman, Andre M., Beijnen, Jos H., Huitema, Alwin D.R., and Opdam, Frans L.

Published
2024

29. Development and validation of an ultra-performance liquid chromatography-tandem mass spectrometry method for the quantification of the antimalarial drug pyronaridine in human whole blood

Author

Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, Schouten, Wietse M., Roseboom, Ignace C., Lucas, Luc, Kabalu Tshiongo, Japhet, Muhindo Mavoko, Hypolite, Kayentao, Kassoum, Rosing, Hilde, Huitema, Alwin D.R., Beijnen, Jos H., Dorlo, Thomas P.C., Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, Schouten, Wietse M., Roseboom, Ignace C., Lucas, Luc, Kabalu Tshiongo, Japhet, Muhindo Mavoko, Hypolite, Kayentao, Kassoum, Rosing, Hilde, Huitema, Alwin D.R., Beijnen, Jos H., and Dorlo, Thomas P.C.

Published
2024

30. Is Higher Docetaxel Clearance in Prostate Cancer Patients Explained by Higher CYP3A? An In Vivo Phenotyping Study with Midazolam

Author

Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, van der Heijden, Lisa T., Ribbers, Claire A., Vermunt, Marit A.C., Pluim, Dick, Acda, Manon, Tibben, Matthijs, Rosing, Hilde, Douma, Joeri A.J., Naipal, Kishan, Bergman, Andre M., Beijnen, Jos H., Huitema, Alwin D.R., Opdam, Frans L., Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, van der Heijden, Lisa T., Ribbers, Claire A., Vermunt, Marit A.C., Pluim, Dick, Acda, Manon, Tibben, Matthijs, Rosing, Hilde, Douma, Joeri A.J., Naipal, Kishan, Bergman, Andre M., Beijnen, Jos H., Huitema, Alwin D.R., and Opdam, Frans L.

Published
2024

32. Impact of loperamide on the pharmacokinetics and tissue disposition of ritonavir-boosted oral docetaxel therapy; a preclinical assessment.

Author

Loos, Nancy H.C., Bui, Viët, de Jong, Daniëlle H., Lebre, Maria C., Rosing, Hilde, Beijnen, Jos H., and Schinkel, Alfred H.

Subjects
RITONAVIR, DOCETAXEL, LOPERAMIDE, PHARMACOKINETICS, CYTOCHROME P-450 CYP3A, CYTOCHROME P-450, DRUG absorption
Abstract

Purpose: An oral docetaxel formulation boosted by the Cytochrome P450 (CYP) 3 A inhibitor ritonavir, ModraDoc006/r, is currently under clinical investigation. Based on clinical data, the incidence of grade 1–2 diarrhea is increased with this oral docetaxel formulation compared to the conventional intravenous administration. Loperamide, a frequently used diarrhea inhibitor, could be added to the regimen as symptomatic treatment. However, loperamide is also a substrate of the CYP3A enzyme, which could result in competition between ritonavir and loperamide for this protein. Therefore, we were interested in the impact of coadministered loperamide on the pharmacokinetics of ritonavir-boosted oral docetaxel. Methods: We administered loperamide simultaneously or with an 8-hour delay to humanized CYP3A4 mice (with expression in liver and intestine) receiving oral ritonavir and docetaxel. Concentrations of docetaxel, ritonavir, loperamide and two of its active metabolites were measured. Results: The plasma exposure (AUC and Cmax) of docetaxel was not altered during loperamide treatment, nor were the ritonavir plasma pharmacokinetics. However, the hepatic and intestinal dispositions of ritonavir were somewhat changed in the simultaneous, but not 8-hour loperamide treatment groups, possibly due to loperamide-induced delayed drug absorption. The pharmacokinetics of loperamide itself did not seem to be influenced by ritonavir. Conclusion: These results suggest that delayed loperamide administration can be added to ritonavir-boosted oral docetaxel treatment, without affecting the overall systemic exposure of docetaxel. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

40. Phase 1 study of the pan-HER inhibitor dacomitinib plus the MEK1/2 inhibitor PD-0325901 in patients with KRAS-mutation-positive colorectal, non-small-cell lung and pancreatic cancer

Author

van Geel, Robin M. J. M., van Brummelen, Emilie M. J., Eskens, Ferry A. L. M., Huijberts, Sanne C. F. A., de Vos, Filip Y. F. L., Lolkema, Martijn P. J. K., Devriese, Lot A., Opdam, Frans L., Marchetti, Serena, Steeghs, Neeltje, Monkhorst, Kim, Thijssen, Bas, Rosing, Hilde, Huitema, Alwin D. R., Beijnen, Jos H., Bernards, René, and Schellens, Jan H. M.

Published
2020
Full Text
View/download PDF

43. Is Higher Docetaxel Clearance in Prostate Cancer Patients Explained by Higher CYP3A? An In Vivo Phenotyping Study with Midazolam

Author

van der Heijden, Lisa T., primary, Ribbers, Claire A., additional, Vermunt, Marit A.C., additional, Pluim, Dick, additional, Acda, Manon, additional, Tibben, Matthijs, additional, Rosing, Hilde, additional, Douma, Joeri A.J., additional, Naipal, Kishan, additional, Bergman, Andre M., additional, Beijnen, Jos H., additional, Huitema, Alwin D.R., additional, and Opdam, Frans L., additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results